List of Excipients in Branded Drug BESPONSA

BESPONSA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 5, 2026

BESPONSA is an antibody-drug conjugate containing inotuzumab ozogamicin, a CD22-directed monoclonal antibody linked to the cytotoxic agent calicheamicin. Its commercial formulation is a sterile lyophilized powder supplied in single-dose vials. The excipient system is deliberately narrow: sucrose provides cryo- and lyoprotection, while polysorbate 80 limits interfacial aggregation during manufacturing, reconstitution, and dilution. The principal commercial opportunities are in high-purity excipient supply, low-peroxide surfactants, lyophilization services, vial and transfer systems, stability testing, and differentiated reconstitution products.

BESPONSA has no conventional small-molecule generic pathway. It is regulated as a biologic under a biologics license application, and future competition would most likely involve a biosimilar or interchangeable biosimilar, subject to the complexity of the antibody-drug conjugate, linker, payload, conjugation profile, and clinical comparability requirements.

What is BESPONSA and how is it formulated?

BESPONSA is approved for adults and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The active ingredient is inotuzumab ozogamicin, an immunoconjugate directed at CD22 and carrying a calicheamicin derivative.

The marketed dosage form is a 1 mg single-dose vial containing sterile lyophilized powder. The product is reconstituted with Sterile Water for Injection and subsequently diluted in 0.9% Sodium Chloride Injection before intravenous infusion. The US prescribing information identifies sucrose and polysorbate 80 as inactive ingredients in the drug product (FDA, 2024).

BESPONSA formulation profile

Attribute	BESPONSA profile
Active ingredient	Inotuzumab ozogamicin
Product class	Antibody-drug conjugate
Target	CD22
Payload	Calicheamicin derivative
Dosage form	Sterile lyophilized powder
Container	Single-dose glass vial
Vial strength	1 mg
Reconstitution medium	Sterile Water for Injection
Dilution medium	0.9% Sodium Chloride Injection
Key excipients	Sucrose and polysorbate 80
Administration	Intravenous infusion
Primary formulation objective	Preserve antibody structure, conjugate integrity, and payload potency through freeze-drying and reconstitution

The limited excipient count does not indicate a simple development problem. ADCs combine a protein, linker, and cytotoxic payload. Each component can respond differently to pH, temperature, oxidation, agitation, light, freeze-thaw cycles, and surface contact. Excipient selection must therefore support the entire conjugate rather than only the antibody.

What do sucrose and polysorbate 80 do in BESPONSA?

Sucrose is the principal stabilizing excipient. It can protect the antibody-drug conjugate during freezing and drying by replacing some of the hydrogen-bonding interactions lost when water is removed. It also contributes to the formation of a stable amorphous matrix in the lyophilized cake.

Polysorbate 80 is a nonionic surfactant. It reduces adsorption to glass, elastomeric components, tubing, filters, and infusion-bag surfaces. It also reduces aggregation caused by agitation and air-liquid interfaces.

Excipient functions and commercial specifications

Excipient or component	Primary function	Key quality risks	Commercial opportunity
Sucrose	Lyoprotection and protein stabilization	Moisture, residual water, cake collapse, particulates	Parenteral-grade low-endotoxin sucrose and formulation screening
Polysorbate 80	Interfacial protection and aggregation control	Peroxide formation, hydrolysis, fatty-acid distribution, particles	Low-peroxide, well-characterized PS80 and oxidation-control packages
Glass vial	Container closure and product protection	Adsorption, delamination, breakage, extractables	Low-adsorption vials and validated container systems
Stopper	Sterile closure	Extractables, leachables, tungsten or silicone interaction	Low-extractables elastomers
Sterile Water for Injection	Reconstitution	Handling errors and aseptic manipulation	Closed-system transfer and reconstitution devices
0.9% sodium chloride solution	Infusion dilution	In-use stability and adsorption to bags or tubing	Ready-to-use dilution systems and compatibility studies

Why is polysorbate 80 a strategic excipient issue for BESPONSA?

Polysorbate 80 is commercially available and generally familiar to injectable manufacturers. Its risk profile is more complex than its routine use suggests. The surfactant can undergo oxidation and hydrolysis, generating peroxides, aldehydes, acids, and free fatty acids. Those degradation products can affect protein aggregation, visible and subvisible particles, potency, and conjugate integrity.

For an ADC, the analytical burden is broader than monitoring antibody aggregation. Developers may need to evaluate:

• Monomer and aggregate content.
• Free payload and unconjugated antibody.
• Drug-to-antibody ratio distribution.
• Linker stability.
• Payload release.
• Oxidative degradation.
• Subvisible and visible particles.
• Potency and target binding.
• Reconstituted and diluted in-use stability.

The highest-value excipient opportunity is therefore not commodity polysorbate 80 alone. It is a qualified, low-variability excipient platform with peroxide control, lot-to-lot characterization, trace-metal control, and compatibility data against ADC drug products.

Could alternative surfactants replace polysorbate 80?

In principle, alternative surfactants such as polysorbate 20 or poloxamers could be evaluated. A change would require more than a simple excipient substitution. The sponsor would need to establish comparable stability, potency, particulate performance, container compatibility, and manufacturing robustness.

For a marketed biologic, changing from polysorbate 80 to another surfactant can trigger comparability and regulatory review. The commercial benefit must exceed the cost of formulation redevelopment, process qualification, stability studies, and regulatory submissions. A supplier with a differentiated low-peroxide polysorbate 80 grade has a more practical near-term opportunity than a supplier promoting an unvalidated replacement surfactant.

What manufacturing and packaging barriers affect BESPONSA excipient commercialization?

BESPONSA is a lyophilized ADC, so the excipient strategy is linked to the freeze-drying cycle and the container-closure system.

Lyophilization barriers

Critical development variables include:

• Freezing rate and ice nucleation.
• Collapse temperature and product temperature.
• Primary drying pressure and duration.
• Secondary drying conditions.
• Residual moisture.
• Cake appearance and reconstitution time.
• Reconstituted concentration and clarity.
• Stability under refrigerated storage.

Sucrose concentration must be balanced against cake structure, reconstitution performance, and residual moisture. Excessive surfactant can increase particle formation or complicate analytical interpretation. Insufficient surfactant can increase adsorption and aggregation.

A commercial excipient supplier can create value by providing formulation-development data across multiple lyophilization cycles rather than selling a material specification alone.

Container-closure and delivery barriers

BESPONSA requires aseptic reconstitution and dilution before infusion. Commercial risks include dose loss on vial walls, adsorption to transfer devices, foaming during reconstitution, and exposure to unsuitable tubing or filters.

Potential products include:

1. Low-binding vial and stopper combinations.
2. Validated reconstitution adapters.
3. Closed-system transfer devices.
4. Low-shear transfer sets.
5. Infusion bags and tubing with demonstrated ADC compatibility.
6. Pharmacy preparation kits.
7. Digital preparation instructions linked to validated handling procedures.

These products may be positioned as workflow and dose-recovery solutions rather than as new BESPONSA formulations.

What patents protect BESPONSA and its excipient strategy?

BESPONSA is protected primarily through biologic, antibody-drug conjugate, linker-payload, manufacturing, and method-of-use rights rather than through a conventional small-molecule Orange Book patent set.

The public FDA product record identifies BESPONSA as a biologic approved under a BLA. The FDA Orange Book generally does not provide the same patent-listing framework for biologics that it provides for small-molecule drugs. Biologic patent information is handled through the statutory patent-exchange process under the Biologics Price Competition and Innovation Act and related Purple Book processes (FDA, 2024a; FDA, 2024b).

Patent categories relevant to BESPONSA

Patent category	Commercial relevance
Anti-CD22 antibody claims	Protect the targeting component and related sequences
Inotuzumab conjugate claims	Protect the antibody-drug conjugate structure
Linker-payload claims	Protect conjugation chemistry and calicheamicin derivatives
Drug-to-antibody ratio and conjugation-process claims	Raise comparability and manufacturing barriers
Pharmaceutical composition claims	May cover stabilized ADC compositions or concentration ranges
Method-of-use claims	Cover treatment of B-cell precursor ALL or specific patient populations
Manufacturing claims	Cover conjugation, purification, filtration, and potency-control steps
Formulation and lyophilization claims	May protect specific stability or processing conditions

The existence, scope, and enforceability of individual patents must be assessed from current patent-family records and prosecution histories. A precise patent-expiration table cannot be stated reliably without a verified family-level review. Patent term for US patents generally depends on the earliest effective nonprovisional filing date, patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable regulatory extension.

When does BESPONSA lose exclusivity?

BESPONSA does not have a single generic-style expiry date. Market exclusivity is determined by several overlapping protections:

• BLA reference-product exclusivity.
• Patent protection for the antibody, ADC, linker, payload, formulation, and manufacturing process.
• Orphan-drug exclusivity, if applicable to the approved indication.
• Regulatory exclusivity associated with pediatric studies or other FDA-designated protections.
• Litigation outcomes and settlement terms.
• The timing of biosimilar approval and commercial launch.

The BPCIA provides 12 years of reference-product exclusivity from first licensure for a qualifying biologic, subject to statutory limitations and product-specific regulatory treatment (FDA, 2024c). BESPONSA was first approved by FDA in August 2017. The statutory reference-product exclusivity period therefore points to a 2029 regulatory benchmark, although patent rights and other exclusivities can extend effective protection beyond or complicate that date.

BESPONSA exclusivity timeline

Event	Date or timing
FDA approval	August 2017
Reference-product exclusivity benchmark	Approximately August 2029
Earliest potential biosimilar pathway timing	Subject to BPCIA requirements and applicable exclusivity
Commercial biosimilar launch	Dependent on patents, litigation, settlement, and FDA approval
Small-molecule ANDA pathway	Not applicable

Are there Paragraph IV challenges to BESPONSA?

A Paragraph IV challenge is an abbreviated new drug application mechanism for small-molecule drugs. It is not the standard route for challenging BESPONSA because BESPONSA is a biologic licensed under a BLA.

The corresponding competitive pathway is a biosimilar application under section 351(k) of the Public Health Service Act. A biosimilar applicant may challenge relevant patents through the BPCIA patent-exchange process, often referred to as the patent dance. The process can lead to patent litigation before commercial launch.

No Paragraph IV strategy should be assumed for BESPONSA. The relevant diligence questions are:

• Whether a biosimilar developer has initiated a BPCIA process.
• Whether the reference product is listed in the FDA Purple Book.
• Which patents are asserted or disclosed.
• Whether the product is eligible for interchangeability.
• Whether the developer has reached a license or launch settlement.
• Whether manufacturing and analytical differences create additional litigation exposure.

What formulation patents could create commercial barriers?

Formulation patents can be important even when the marketed excipient list is short. Potential claim areas include:

• Sucrose-to-ADC concentration ratios.
• Polysorbate 80 concentration ranges.
• Low-peroxide surfactant compositions.
• Lyophilized cakes with defined residual moisture.
• Reconstitution concentrations.
• Diluted infusion concentrations.
• Stability after reconstitution.
• Stability in saline and specific infusion containers.
• Particle-control methods.
• Container-closure combinations.
• Freeze-drying cycles linked to product quality attributes.

A supplier seeking freedom to operate should distinguish between a formulation that uses the same excipients and a formulation that falls within a protected concentration, process, or stability claim. Substituting a supplier or changing excipient grade usually does not avoid a composition patent if the claim is defined by the product’s final formulation.

How strong is the BESPONSA patent estate?

The BESPONSA estate is likely stronger at the biologic and manufacturing levels than at the commodity-excipient level. Sucrose and polysorbate 80 are established pharmaceutical excipients and are not, by themselves, likely to provide durable exclusivity for the product.

The stronger barriers are more likely to arise from:

• The specific anti-CD22 antibody.
• The conjugated calicheamicin payload.
• Linker and conjugation chemistry.
• Drug-to-antibody ratio control.
• Purification and analytical release methods.
• Clinical methods of use.
• Product-specific stability and manufacturing claims.

For a biosimilar developer, the central technical challenge is demonstrating similarity across a heterogeneous ADC rather than reproducing the excipient list. The developer must address molecular weight, aggregation, charge variants, glycosylation, conjugation sites, drug-to-antibody ratio, free payload, potency, and impurity profiles.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are specialized and qualification-driven.

Low-peroxide polysorbate 80

A supplier can differentiate through:

• Lower and more consistent peroxide levels.
• Defined fatty-acid composition.
• Reduced particle burden.
• Improved oxidation monitoring.
• Small-batch supply for biologics.
• Regulatory support packages.
• Multi-site manufacturing redundancy.

A lower price alone is unlikely to displace a qualified supplier in a marketed ADC.

Pharmaceutical-grade sucrose

Commercial value can come from:

• Low endotoxin.
• Controlled bioburden.
• Low moisture.
• Consistent particle size.
• Reliable supply during lyophilization campaigns.
• Documentation supporting global regulatory filings.

Sucrose is less technically differentiated than polysorbate 80, but supply continuity and lot consistency can be decisive.

Analytical and stability services

Contract laboratories can support:

• Forced-degradation studies.
• Polysorbate oxidation monitoring.
• ADC aggregation and particle testing.
• Reconstituted and diluted in-use stability.
• Container-closure compatibility.
• Extractables and leachables.
• Comparability after excipient or packaging changes.

These services have a higher margin potential than bulk excipient sales because they are tied to regulatory submissions and process changes.

Pharmacy and hospital preparation systems

BESPONSA preparation involves reconstitution and infusion handling. Products that reduce preparation time, dose loss, contamination risk, or operator variability could support institutional purchasing. The strongest value proposition is workflow standardization supported by compatibility and stability data.

What is the FDA regulatory status of BESPONSA?

FDA approved BESPONSA in 2017 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The product is a biologic ADC, not a small-molecule drug subject to an ANDA. Its regulatory status places emphasis on BLA supplements, postmarketing commitments, biologic comparability, and biosimilar competition.

Any new excipient, alternate grade, packaging system, or ready-to-use presentation would require an assessment of whether the change affects product quality, safety, efficacy, or manufacturing controls. The regulatory pathway would depend on whether the change is made by the BLA holder, a contract manufacturer, or a third-party supplier.

How does BESPONSA compare with MYLOTARG?

BESPONSA and MYLOTARG are both calicheamicin-based antibody-drug conjugates, but they target different antigens and address different hematologic malignancies.

Attribute	BESPONSA	MYLOTARG
Active ingredient	Inotuzumab ozogamicin	Gemtuzumab ozogamicin
Target	CD22	CD33
Primary disease area	B-cell precursor ALL	Acute myeloid leukemia
Payload class	Calicheamicin derivative	Calicheamicin derivative
Product type	Lyophilized ADC	Lyophilized ADC
Key formulation lesson	Surfactant and lyoprotectant control for ADC stability	Similar need for conjugate, payload, and particle control
Biosimilar complexity	High	High
Commercial overlap	Limited clinical overlap	Limited clinical overlap

The comparison is commercially relevant because development experience with one calicheamicin ADC can inform analytical methods, surfactant selection, conjugate stability, and manufacturing controls for the other. It does not establish formulation equivalence or freedom to operate.

What generic or biosimilar launch risks exist?

The probability of a near-term conventional generic launch is effectively absent because BESPONSA is not an ANDA product. The more relevant risk is a later biosimilar launch.

Principal biosimilar risks

1. Analytical complexity. ADCs require characterization of both the antibody and the attached payload.
2. Manufacturing opacity. Critical process parameters can affect conjugation-site distribution and drug-to-antibody ratio.
3. Clinical uncertainty. Regulators may require a tailored clinical package if analytical similarity leaves residual uncertainty.
4. Patent litigation. Composition, process, and use patents can delay launch.
5. Hospital adoption. Oncology centers may be cautious about substituting a complex ADC, particularly where interchangeability has not been established.
6. Small market size. A relatively specialized indication may limit the economic incentive for multiple biosimilar entrants.
7. Cold-chain and preparation requirements. Manufacturing and distribution costs can reduce the discount available to competitors.

What is the revenue exposure for Pfizer?

Pfizer reports BESPONSA within its broader product portfolio and does not generally disclose a standalone revenue figure in its principal annual-report tables. Revenue exposure should therefore be modeled using prescription volume, treatment duration, dosing by body-surface area, geographic mix, price concessions, and the size of the relapsed or refractory B-cell precursor ALL population rather than relying on a separately reported product line.

Commercial sensitivity is driven by:

• Continued use in later-line ALL.
• Competitive positioning against other salvage therapies.
• Treatment-center capacity.
• Patient access and reimbursement.
• Potential biosimilar entry after the reference-product exclusivity period.
• Any expansion into earlier-line treatment or new patient subsets.

A supplier’s opportunity is more likely to be measured by recurring qualified-material demand and switching costs than by absolute BESPONSA revenue.

Key Takeaways

• BESPONSA is a lyophilized inotuzumab ozogamicin ADC supplied in a 1 mg single-dose vial.
• Its principal excipients are sucrose and polysorbate 80.
• Sucrose supports lyophilization, while polysorbate 80 limits interfacial aggregation and adsorption.
• Low-peroxide, well-characterized polysorbate 80 is the most technically differentiated excipient opportunity.
• Conventional Paragraph IV litigation is not the relevant framework because BESPONSA is a biologic.
• Biosimilar competition would proceed under the BPCIA 351(k) pathway.
• FDA approval occurred in August 2017, creating an approximately 2029 reference-product exclusivity benchmark under the 12-year biologic exclusivity framework.
• The strongest intellectual-property barriers are likely to involve the ADC structure, linker-payload chemistry, antibody, manufacturing process, and methods of use.
• Commercial opportunities extend beyond bulk excipients to lyophilization, analytical testing, container closure, reconstitution systems, and infusion compatibility.
• BESPONSA revenue is not separately disclosed by Pfizer in a way that supports a reliable standalone figure.

FAQs About BESPONSA Excipients and Commercial Strategy

What is the most important excipient in BESPONSA?

Polysorbate 80 is the most technically sensitive excipient because oxidation and hydrolysis products can affect aggregation, particles, potency, and ADC integrity. Sucrose remains essential for lyophilized-product stability.

Can BESPONSA be reformulated with polysorbate 20?

Polysorbate 20 could be investigated during formulation development, but substitution would require comparability, stability, particulate, potency, and regulatory evaluation. It would not automatically create a commercially interchangeable product.

Is BESPONSA eligible for an interchangeable biosimilar?

A biosimilar developer could seek interchangeability under the applicable FDA pathway, but eligibility would depend on FDA review of the complete application. The complexity of the ADC may increase the analytical and clinical burden.

Do BESPONSA excipients create standalone patent protection?

Sucrose and polysorbate 80 as commodity excipients are unlikely to provide meaningful standalone exclusivity. Protection may arise from product-specific concentration ranges, lyophilization conditions, stability characteristics, or combination claims.

Which supplier capability has the highest commercial value for BESPONSA?

A supplier combining low-peroxide polysorbate 80, ADC compatibility data, global regulatory documentation, and reliable supply is likely to have greater value than a supplier offering an undifferentiated commodity grade.

References

1. Food and Drug Administration. (2024). BESPONSA (inotuzumab ozogamicin) prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024a). Drugs@FDA: BESPONSA application information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024c). Questions and answers on biosimilar development and the BPCI Act. U.S. Department of Health and Human Services.

5. Food and Drug Administration. (2017). FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. U.S. Department of Health and Human Services.

6. Pfizer Inc. (2024). Annual report. Pfizer Inc.

7. European Medicines Agency. (2024). Besponsa: EPAR product information. European Union.